Innovative Access Arrangements and Managed Entry: What Canada Can Learn From Europe

Although Europe’s healthcare systems – and pharmaceutical markets – are different from Canada’s, their experience of managed entry and innovative access arrangements can offer some valuable lessons. All three countries focused on in the report have developed national managed entry strategies. A growing number of payers in many countries are looking to managed entry agreements (MEAs) and other innovative access arrangements (IAAs) to allow rapid access to medicines that address significant unmet needs. In some cases, these medications require additional evidence to fully access their value. There are numerous types of MEAs, but they can be categorized into three broad approaches serving different objectives: (1) financially based schemes to control budget impact; (2) outcomes-based agreements (OBAs) to manage variable drug response rates; and (3) coverage with evidence development to tackle uncertainty about a drug at launch.

Read the report here.